Jan 14 BioMarin Pharmaceutical Inc saidon Thursday the U.S. Food and Drug Administration had rejectedits drug to treat a rare muscle-wasting disorder.

The drug, Kyndrisa, was expected to be the first treatmentin the United States for the disorder that affects one in 3,600newborn boys and causes rapid muscle degeneration. (Reporting by Amrutha Penumudi in Bengaluru; Editing by SavioD'Souza)